Original Source(s)
Related Content
Aptamer Tests Face the Validation Challenge
Clinical adoption will require reproducibility, quality control, and evidence of diagnostic utility
October 6, 2026
-
3 min
Bloodstream Infection Results in Hours
Early results support further clinical validation of a direct-from-blood diagnostic workflow
September 25, 2026
-
3 min
FDA approves combo for ESR1-mutated breast cancer
In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.
September 21, 2026
-
2 min
